Omeros shares are trading lower after the company announced it will discontinue the ARTEMIS-IGAN trial, which did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo.
Benzinga Newsdesk - Oct 16, 2023, 8:52AM